EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 93 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,348 | -56.8% | 50,322 | -0.2% | 0.00% | – |
| Q2 2023 | $35,494 | -30.9% | 50,416 | -12.1% | 0.00% | – |
| Q1 2023 | $51,384 | -6.5% | 57,345 | +23.1% | 0.00% | – |
| Q4 2022 | $54,958 | -46.6% | 46,575 | +244.9% | 0.00% | – |
| Q3 2022 | $103,000 | -10.4% | 13,504 | -25.8% | 0.00% | – |
| Q2 2022 | $115,000 | -38.5% | 18,209 | -19.0% | 0.00% | – |
| Q1 2022 | $187,000 | +17.6% | 22,490 | -26.4% | 0.00% | – |
| Q4 2021 | $159,000 | +26.2% | 30,556 | +61.8% | 0.00% | – |
| Q3 2021 | $126,000 | -30.0% | 18,887 | -10.2% | 0.00% | – |
| Q2 2021 | $180,000 | -4.8% | 21,025 | -1.5% | 0.00% | – |
| Q1 2021 | $189,000 | -74.4% | 21,339 | -64.5% | 0.00% | – |
| Q4 2020 | $738,000 | +46.1% | 60,038 | -3.3% | 0.00% | – |
| Q3 2020 | $505,000 | -19.8% | 62,087 | -5.3% | 0.00% | – |
| Q2 2020 | $630,000 | +34.3% | 65,572 | -5.0% | 0.00% | – |
| Q1 2020 | $469,000 | -28.9% | 68,994 | +55.7% | 0.00% | – |
| Q4 2019 | $660,000 | +111.5% | 44,312 | +45.6% | 0.00% | – |
| Q3 2019 | $312,000 | +9.1% | 30,436 | +13.0% | 0.00% | – |
| Q2 2019 | $286,000 | -34.3% | 26,942 | -13.3% | 0.00% | – |
| Q1 2019 | $435,000 | +65.4% | 31,088 | +20.1% | 0.00% | – |
| Q4 2018 | $263,000 | +26.4% | 25,884 | +49.6% | 0.00% | – |
| Q3 2018 | $208,000 | +7.2% | 17,303 | +8.8% | 0.00% | – |
| Q2 2018 | $194,000 | +7.8% | 15,903 | -12.6% | 0.00% | – |
| Q1 2018 | $180,000 | +328.6% | 18,203 | +506.8% | 0.00% | – |
| Q4 2017 | $42,000 | +23.5% | 3,000 | -2.6% | 0.00% | – |
| Q3 2017 | $34,000 | 0.0% | 3,080 | -28.2% | 0.00% | – |
| Q2 2017 | $34,000 | +325.0% | 4,287 | +481.7% | 0.00% | – |
| Q1 2017 | $8,000 | +14.3% | 737 | +28.8% | 0.00% | – |
| Q4 2016 | $7,000 | +16.7% | 572 | +34.3% | 0.00% | – |
| Q3 2016 | $6,000 | +500.0% | 426 | +517.4% | 0.00% | – |
| Q2 2016 | $1,000 | – | 69 | +165.4% | 0.00% | – |
| Q1 2016 | $0 | – | 26 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |